Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after reporting full year 2025 earnings, moving from a prior net loss to US$1.4b in net income on US$17.3b in sales.

The recent earnings beat and return to profitability have gone hand in hand with a strong share price run, with a 90 day share price return of 66.57% and a 1 year total shareholder return of 96.43% suggesting momentum has been building over both shorter and longer periods.

If Teva’s move has you looking at other drugmakers, this could be a useful moment to scan healthcare stocks for more healthcare names that fit your criteria.

With Teva back in the black and the share price near recent highs, the key question now is whether the current valuation still leaves a margin of safety or if the market is already pricing in future growth.

Most Popular Narrative: 3.5% Undervalued

Teva Pharmaceutical Industries' most followed narrative pegs fair value at $35.32 versus the last close of $34.08, putting a small valuation gap in focus for investors.

Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.

Curious what is baked into that fair value? The narrative leans heavily on future earnings power, margin shifts, and a richer mix of branded and biosimilar revenue. The exact hurdles and assumptions sit under the hood.

Result: Fair Value of $35.32 (UNDERVALUED)

However, this depends on a few pressure points, particularly heavy debt above US$15b and the risk that key branded drugs underperform expectations.

Another Take: Multiples Flash a Different Signal

While the narrative and DCF style fair value point to a modest undervaluation, Teva’s current P/E of 27.7x sits above both the US pharmaceuticals average of 20.4x and its own fair ratio of 25.5x. That richer multiple suggests less room for error if growth or margins fall short. How comfortable are you with that cushion?

Build Your Own Teva Pharmaceutical Industries Narrative

If parts of this story do not quite line up with your own view, or you prefer building your stance straight from the numbers, you can spin up a personalised thesis in just a few minutes with Do it your way.

A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Do not stop your research with one stock. Broaden your watchlist now so you can spot opportunities early instead of hearing about them after the move.

• Target potential gains at the small end of the market by reviewing these 3535 penny stocks with strong financials that still show solid financial underpinnings.
• Monitor technology shifts by scanning these 24 AI penny stocks capturing real use cases across automation, data analytics, and software.
• Focus on price versus fundamentals with these 886 undervalued stocks based on cash flows that may trade below what their cash flows suggest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.